Sermorelin

Overview

The shortest biologically active fragment of GHRH. It has a legitimate history as a diagnostic agent and a large off-label life in anti-aging clinics, where the evidence is far thinner than the marketing suggests.

How it works

Binds pituitary GHRH receptors, producing a brief GH pulse that mirrors natural nocturnal secretion. Because the pituitary remains in charge, somatostatin feedback caps the response — which is both its safety feature and its efficacy ceiling.

Evidence base

Rated 3 of 5 — Moderate. Small or early-phase human trials, or good controlled topical human data.

• Strong evidence for the original pediatric diagnostic indication.
• Weak evidence for the adult wellness indications it is now mostly used for.

Benefits & potential uses

Bars indicate how well each claim is supported: three = strong human evidence, two = moderate, one = preliminary or preclinical.

• Physiological GH pulses Moderate evidence

  Raises GH without the flat supraphysiologic levels of injected recombinant GH, preserving feedback regulation.

• Documented efficacy in GH-deficient children Strong evidence

  Older controlled data support growth velocity improvement in true deficiency.

• Well tolerated in short-term use Moderate evidence

  Decades of clinical use with a mild side-effect profile.

• Low risk of pituitary suppression Moderate evidence

  Unlike exogenous GH, it does not shut down the endogenous axis.

• Reported sleep and recovery improvement Preliminary

  Commonly described by users; largely uncontrolled data, plausible given GH secretion is sleep-linked.

Risks, cons & cautions

Bars indicate seriousness: three = serious or common, two = moderate, one = minor.

• Weak evidence for adult anti-aging use Moderate evidence

  The body-composition, energy and longevity claims made in wellness clinics have not been tested in adequate randomized trials.

• Very short half-life Minor

  Requires frequent dosing and produces only a transient signal.

• Glucose intolerance with sustained GH elevation Moderate evidence

  A class effect of raising the GH/IGF-1 axis.

• Injection-site reactions and flushing Minor

  Common and generally minor.

• Compounding variability Moderate evidence

  Potency and sterility depend entirely on the compounding pharmacy; product quality is not uniform.

• Contraindicated in active malignancy Serious

  Standard caution with any GH-axis stimulation.

Who should avoid it

• Active malignancy
• Pregnancy
• Untreated diabetes (relative)
• Known hypersensitivity

If used under medical supervision, monitor

• IGF-1 as a surrogate for GH exposure
• Fasting glucose and HbA1c
• Symptoms of fluid retention or joint pain

Interactions

Not exhaustive. Always have a pharmacist or physician review your full medication list — including supplements.

• Corticosteroids — suppress the GH response
• Thyroid hormone — affects GH axis testing and response
• Insulin and antidiabetic drugs — GH elevation opposes insulin action

Regulatory & legal status

No longer an approved US drug product; lawful access is via patient-specific compounding under a prescription. FDA has scrutinised this category closely.

Infographic

Sermorelin — benefits & risks at a glance Download SVG

Where to read further

We link to live literature searches rather than a frozen citation list, so you always see current results — including anything published after our last review.

• PubMed — all published literature on Sermorelin
• PubMed — randomized controlled trials only
• ClinicalTrials.gov — registered human trials

Related peptides in Growth Hormone Axis